Update on the management of chronic hepatitis B

Reviews in Gastroenterological Disorders

Volumn 2, Issue 3, 2002, Pages 106-115

  Davis, Gary L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Alanine aminotransferase; Hepatitis B virus; Human immunodeficiency virus; Interferon; Lamivudine; Liver

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ALPHA2A INTERFERON; ANTIVIRUS AGENT; CORTICOSTEROID; DEOXYCYTIDINE; DEOXYGUANOSINE DERIVATIVE; DNA POLYMERASE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; GLYCOPROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; ISOLEUCINE; LAMIVUDINE; METHIONINE; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; PLACEBO; PRODRUG; RECOMBINANT ALPHA INTERFERON; THYMIDINE DERIVATIVE; THYMOSIN; THYMOSIN ALPHA1; UNINDEXED DRUG; VALINE; VIRUS DNA;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; COMORBIDITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MORBIDITY; NEPHROTOXICITY; REVIEW; SEROLOGY; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; PHOSPHONIC ACIDS;

EID: 0036592531     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Management of hepatitis B 2000 - Summary of a workshop
2. Hepatitis B virus infection
3. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls
4. Chronic hepatitis
5. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
6. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
7. AASLD Practice Guidelines: Chronic hepatitis B
8. The interferon system in acute and chronic viral hepatitis
9. Interferon in viral hepatitis: Role in pathogenesis and treatment
10. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis
11. Interferons and their actions
12. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B
13. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
14. Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP)
15. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial
16. 40 KDa PEG-interferon alfa-2a (Pegasys): Efficacy and safety results from a phase II, randomized, actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B
17. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
18. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
19. Long-term follow-up of patients with chronic hepatitis B treated with interferon
20. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
21. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan
22. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection
23. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications
24. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B
25. A preliminary trial of lamivudine for chronic hepatitis B infection
26. A one-year trial of lamivudine for chronic hepatitis B
27. Lamivudine as initial treatment for chronic hepatitis B in the United States
28. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
29. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
30. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B
31. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen sero-conversion rates: Results after 3 years of therapy
32. Predictors of HBsAg seroconversion in chronic hepatitis B patients treated with lamivudine
33. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B
34. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
35. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
36. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
37. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
38. Clinical potential of emerging new agents in hepatitis B
39. The effect of longer duration of harboring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients
40. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial
41. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy
42. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study
43. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
44. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies
45. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial
46. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
47. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B
48. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
49. Emtricitabine (FTC): Results from a 24-week dose-selection trial in patients with chronic HBV infection
50. HBeAg profile in patients with chronic HBeAg positive hepatitis B treated with Emtricitabine (FTC) for 1 year
51. Safety and efficiacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection
52. Antiviral L-nucleosides specific for hepatitis B virus infection
53. Clinical trial update: Novirio Pharmaceuticals
54. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase-therapeutic implications
55. A randomized controlled trial of thymosin-alpha 1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B
56. Efficacy of thymosin alpha 1 in patients with chronic hepatitis B: A randomized, controlled trial
57. Thymosin alpha 1 treatment of chronic hepatitis B: Results of a phase III multicenter, randomized, double-blind and placebo-controlled study
58. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
59. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg
60. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B
61. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon
62. The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B
63. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long-term cohort study
64. Efficacy of lamivudine in patients with hepatitis B e antigen-negative hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
65. Long-term follow-up of patients with anti-HBe/HBV DNA positive chronic hepatitis B treated for 12 months with lamivudine
66. Extended lamivudine treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B
67. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
68. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment
69. Role of hepatitis C virus in dual and triple hepatitis virus infection
70. A meta-analysis of interferon-alpha treatment of hepatitis D virus infection
71. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon on alpha-2B. Results of a randomized controlled trial
72. Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy
73. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus
74. Lamivudine for chronic delta hepatitis
75. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection
76. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: Long term results of a prospective randomized trial
77. Coinfection by hepatitis B virus and hepatitis C virus
78. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
79. Mortality for liver disease in patients with HIV infection: A cohort study
80. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection
81. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
82. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV III antibodies to recombinant alpha interferon
83. Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population
84. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
85. Primary infection with a lamivudine-resistant hepatitis B virus
86. Low-dose adefovir for the treatment of chronic hepatitis B in HIV-infected people
87. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study
88. Survival in chronic hepatitis B. An analysis of 379 patients
89. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B
90. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus
91. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine
92. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort
93. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis
94. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis b infection
95. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
96. A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002